Zalutumumab (powder)
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 667901-13-5
- Peso molecular:146.52 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas EGFR
More
Actividad biológica
Descripciòn
Species Reactivity
Human
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
Aplicación
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 667901-13-5
-
Peso molecular 146.52 kDa
-
SMILES
[Zalutumumab (powder)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Schick U, et al. Zalutumumab in head and neck cancer. Expert Opin Biol Ther. 2012 Jan;12(1):119-25. [Content Brief]
[2]. Lammerts van Bueren JJ, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6109-14. [Content Brief]
[3]. Overdijk MB, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 2011 Sep 15;187(6):3383-90. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zalutumumab (powder) Related Classifications
HY-P99155A Related Classifications
Powered by Bioz